Using Targeted Methylation Sequencing to Bring Epigenetic Biomarkers to the Clinic

Join Agilent and leading researchers as they share how they're navigating complex biology, exploring new scientific galaxies, and charting pathways to breakthrough therapies. From unlocking cellular mysteries to uncovering molecular insights, discover how today's innovations are helping propel research toward its next giant leap.

All attendees with be automatically entered into a drawing to win a FREE Tablet!

Part 1: Using Targeted Methylation Sequencing to Bring Epigenetic Biomarkers to the Clinic

Methylation is an increasingly important layer of biological regulation, disease heterogeneity, and clinical phenotype, yet many discovery workflows remain constrained by predefined array content, bisulfite-associated DNA damage, amplification bias, and limited molecular context. Native-read nanopore sequencing enables direct measurement of DNA sequence and methylation from the same molecule, preserving information across CpGs, variants, repetitive elements, and haplotypes. This webinar will describe a discovery-to-impact model in which genome-wide native methylome sequencing identifies informative epigenetic features, and Agilent SureSelect-enabled targeting converts those discoveries into high-depth, multiplexed assays for translational and clinical research. Applications include tissue-of-origin analysis, oncology, rare disease, and other settings where integrated genetic and epigenetic readouts may improve biological interpretation and clinical utility.

Presenter: Jonathon Hill, PhD (Co-founder and Vice President of Science and Technology, Renew Biotechnologies)

Jonathon T. Hill, PhD, is Vice President of Science and Technology at Renew Biotechnologies, where he co-leads scientific innovation across the company’s native-read nanopore sequencing, assay development, and translational research programs. He is also a co-founder of Renew Labs and The Robertson Endowed Professor of Cell Biology and Physiologyat Brigham Young University. His work spans genomics, epigenetics, bioinformatics, and long-read sequencing, focusing on advancing new molecular technologies toward scalable research and clinical applications.